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The HIV pandemic has had a major impact on the epidemiological dynamics of tuberculosis. 
In countries with a severe HIV epidemic, there has been a dramatic rise in the notification rates 
for tuberculosis (TB). The results of various studies1,2,3 have documented that persons co 
infected with Mycobacterium tuberculosis and HIV have a 5.8% annual risk and a 30% or 
greater life time risk of developing active TB, The mechanisms include reactivation of latent 
infection; rapid progression of primary infection3 or reinfection with Mycobacterium 
tubercuiosis4. 
UNAIDS estimates that of the global total of 37.8 million people living with HIV at the end of 
2003,70.1% are in sub-Saharan Africa and 16.1% are in South East Asia5. About a third of the 
people living with HIV worldwide are co infected with Mycobacterium tuberculois6. Since 68% 
of those co infected live in Sub Saharan Africa, this region caries the overwhelming burden of 
global epidemic of HIV associated tuberculosis. In sub Saharan Africa 20 to 67% of patients 
with pulmonary tuberculosis have been reported to be HIV seropositive7 However, with 22% 
of those co infected living in this region, South East Asia also bears a considerable burden of 
HIV associated TB. In other regions with a high number of AIDS cases. an increased HIV 
prevalence rate has been noted among TB  patients8,9,10. 
HIV is the major cause of the large increase over the last decade in the incidence of tuberculosis 
in populations with a high prevalence of HIV infection. In South India. one of the early 
observations in 1992 has shown that a significant proportion of AIDS cases detected, had 
active tuberculosis11. The increased risk of developing TB disease among those infected with 
HIV has prompted a need to reconsider institution of preventive measures to enable HIV 
seropositive patients to avoid the risk of progression to clinical TB. Four types of intervention 
are available for TB control, namely, case finding and treatment, preventive therapy use of 
BCG vaccination and environmental measures12. Emphasis in developing countries has 
been on case finding and treatment and on provision of BCG vaccination to infants. Preventive 
therapy was not recommended except for breastfeeding infants of mothers with pulmonary 
tuberculosis or other children under 5 years of age living with infectious persons13. 
Preventive therapy (PT) or chemoprophylaxis against tubercuiosis is the use of one or more 
anti- tuberculosis drugs (AT) given to persons with latent infection with Mycobacterium 
tuberculosis in order stop or prevent the progression to active disease Prior to the HIV 
epidemic, its use in countries with a high prevalence-of tuberculosis was limited to childhood 
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contacts of active cases since these children have a higher risk of progression to disseminated 
and severe forms of disease. Evaluation of preventive therapy, before the emergence of 
AIDS, involving over 100,000 participants in a placebo-controlled trial demonstrated a reduction 
of tuberculosis of 25-92%14. Several studies have now demonstrated that preventive therapy 
is effective in preventing progression of ruberculosis infection in individuals dually infected 
with HIV and M.tuberculosis, although the efficacy is not 100% (ranges from 60-90%). In 
addition, there is a suggestion that chemoprophylaxis may delay HIV disease progression 
amongst asymptomatic HIV infected individuals15. 
The increased risk of developing active disease associated with HIV infection has provoked 
a number of questions, regarding who should receive prophylactic therapy, how long it 
should be continued. whether isoniazid alone is the most effective agents role of secondary 
prophylaxis etc. Clinical trials are ongoing in these areas and some data are available, 
Ideal candidate for chemoprophylaxis 
The risk of developing active tuberculosis in HIV infected persons with positive tuberculin 
(PPD), skin test reactions may be as high as 7.9% per year, in a study by Selwyn and 
colleagues2 in a methadone maintenance programme in New York. All of these cases occurred 
in patients who did not take prophylactic isoniazid and occurred among those with a positive 
PPD, Swaminathan et al16 reported an incidence rate of 7.1 per 100 person years in PPD 
Positive and 6.9 per 100 person years in PPD negative HIV positive individuals in South India. 
A meta analysis17 of 7 randomized controlled clinical trials to determine the efficacy of isoniazid 
(INH) for the prevention of TB in tuberculin skin test positive and negative individuals with HIV 
infection was carried out which revealed that in groups of tuberculin skin test positive and 
negative persons, the risk ratio of TB was 0.40 (95% CI, 0.24-0.65) and 0.84 (95% Cl. 0.54- 
1.30), respectively and the difference in the effectiveness of INH versus placebo between 
these groups was statistically significant (P=0.03); consistency of results was found across 
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trials for all comparisons. Another meta analysis18, on the effectiveness of tuberculosis 
preventive therapy in reducing the risk of active tuberculosis and death in HIV infected 
persons, analyzed 11 different preventive therapy trials with a total of 8,130 randomized 
participants. The result of this meta analysis shows that the benefit was more in individuals 
with a positive tuberculin skin test (RR 0.38, 95% CI 0.25 to 0.57) than in those who had a 
negative test (RR 0.83.95% CI 0.58 to 1.18). A positive tuberculin skin test is defined as an 
induration of ³ 5mm in HIV-1 seropositive persons. These observations have led to the 
recommendation that all HIV infected patients should undergo tuberculin skin testing and 
persons with a positive tuberculin skin test be offered preventive therapy with isoniazid (INH), 
after ruling out active tuberculosis. 
A study among injecting drug users in Baltimore, Maryland19 found that there was a 
considerable change in the delayed type hypersensitivity (DTH) status over time. 
particularly among HIV infected persons with lower CD4 cell counts. Some have 
suggested that establishing the likelihood of Mycobacterium tuberculosis infection on 
grounds other than skin testing is a more useful means for determining who should 
receive prophylactic therapy20. However, at present, there is no surrogate test for M. 
tuberculosis latent infection that is consistently better than the tuberculin skin test. Factors 
such as community rates of infection and active disease, demographic information, 
history of exposure and abnormalities on chest radiographs can all be used to identify 
those HIV infected patients at highest risk. These individuals may be considered for 
prophylactic therapy regardless of skin test results 
The CDC has recommended that preventive therapy for anergic HIV infected persons 
be considered if the patient has had known contact with an active TB case or belongs 
to a group in which the prevalence of TB infection is at least 10%21. In areas endemic for 
TB and HIV, PPD or tuberculin test may not be helpful in identifying persons who could 
benefit from INH prophylaxis. Among TB patients with HIV infection, upto 40% could be 
anergic22. This further complicates the issue of tuberculosis preventive therapy among 
individuals infected with HIV. 
Chemoprophylaxis in tuberculin negative HIV infected persons 
Tuberculin skin test negative, HIV infected persons from high-risk groups or from areas 
with a high prevalence of Mycobacterium tuberculosis infection may be at increased risk of 
primary or reactivation tuberculosis. Some experts recommend preventive therapy for 
persons in this category. The efficacy of preventive therapy in Mantoux or PPD negative HIV 
positive persons has not been clearly established, most studies showing it to be of limited 
value. In a meta analysis23 combining the various studies on efficacy of preventive therapy 
in subjects with a negative PPD test, INH was found to be significantly better than placebo 
with a rate ratio of 0.57 (95% CI 0.41 to 0.79). Hence in HIV seropositive individuals with 
negative Mantoux or in situations where mantoux cannot be performed living in a high 
prevalence TB region, chemoprophylaxis with INH will reduce the risk of developing active 
TB in the short term to around 60% of what it would have been without such treatment. 
Hence the target population for preventive therapy among HIV seropositives should be 
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All PPD positive HIV infected individuals who donot have active tuberculosis 
When PPD testing is not feasibie - 
those living in areas with a high prevalence of TB infection (>30%) 
health care workers 
household contacts of TB patients 
prisoners and miners 
other selected groups at high risk of acquisition or transmission of TB. 
Prerequisites to initiate Preventive therapy 
Prior to starting an individual on preventive treatment for tuberculosis, it is essential to 
ensure that he/she does not have active tuberculosis. This is done by a complete 
clinical examination along with a chest x-ray and sputum smear examination for acid- 
fast bacilli (AFB). It is advisable that chest x-ray is done for every individual before 
considering preventive therapy. Any HIV infected patient with fever, cough or abnormal 
chest x-ray should not be given preventive treatment until a full evaluation has been 
done and it is confirmed that active TB disease is not present. At times, it is difficult to 
exclude TB even when the chest radiograph is normal and three sputum smears are 
negative for AFB24. Therefore preventive therapy should only be used in settings where 
it is possible to exclude active TB cases and to ensure appropriate monitoring and 
follow up. 
Duration of preventive therapy 
A multicentric trial conducted in the U.S.A.. Mexico, Brazil and Haiti25 demonstrated that 
the magnitude of protection obtained from a regimen of isoniazid administered daily 
for 12 months was similar to that obtained from a regimen of rifampicin and pyrazinamide 
administered daily for 2 months. Moreover, it was noted that persons taking rifampin 
and pyrazinamide for 2 months were significantly more likely (80%) to complete therapy 
than those persons taking isoniazid for 12 months (69%). However, due to several 
cases of fatal hepatoxicity reported among HIV-negative individuals on this regimen, it 
is no longer recommended for preventive therapy. A study amongst HIV infected 
persons in Uganda26 evaluated a 6-month regimen with a placebo comparison group 
and demonstrated a 70% reduction in the incidence of tuberculosis among persons in 
the treatment group 
In another trial by Halsey et al27 researchers found similar overall protection against 
tuberculosis in 2 groups of Mantoux positive, HIV infected persons: those who took 
partially supervised isoniazid twice weekly for 6 months and those who took rifampin 
and pyrazinamide twice weekly for 2 months. There was no significant difference in total 
mortality rates at any time between both the groups. 
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Another trial in Ugandan adults28 infected with human immunodeficiency virus studied three 
regimens namely isoniazid daily for 6 months versus isoniazid with rifampicin daily for 3 
months and isoniazid with rifampicin and pyrazinamide daily for 3 months along with a 
placebo group. 80-89% of different groups completed treatment and the mean follow up 
duration was 15 months. This study demonstrated an 83% reduction in the incidence of 
tuberculosis among persons in the treatment groups as compared to the placebo group. It 
was also noted that the advantage of shorter regimens was better patient compliance and 
earlier sterilization of any lesions, however, the risk of drug toxicity was higher. 
The evidence to date suggests that preventive therapy is efficacious in HIV positive persons 
with tuberculin reactions > 5mm, and that optimal duration of isoniazid preventive therapy 
(using a single drug) should be greater than six months to provide the maximum degree of 
protection against TB. Although the American Thoracic Society29 has recommended that 
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isoniazid therapy be continued for 12 months in persons with HIV infection, there are only few 
studies comparing the efficacy of this approach with that of either shorter or longer courses. 
There has been some suggestion that the effect of prophylaxis tends to wane, as time 
passes". However, no long-term follow-up studies are available to confirm this. 
Rhythm of administration of preventive therapy 
HIV seropositive patients in Haiti27, who received either isoniazid twice weekly for six months 
or rifampicin with pyrazinamide twice weekly for 2 months were studied, the rate of development 
of activeTB was similar in the two groups after 3 years; but patient who received rifampicin 
and pyrazinamide had significantly more cases of activeTB during the first 10 months. 
In another study in which isoniazid was administered twice a week (10-15mg/kg, with a 
maximum dose of 900mg) to a cohort of injecting drug users under Directly Observed 
Preventive Therapy (DOPT), the findings support the efficacy of twice weekly isoniazid 
preventive therapy31. Twice weekly regimens with DOP were used in the study with the hope 
that supervised delivery of therapy would enhance adherence with preventive therapy regimen. 
Thus the available data suggests that the protection obtained from preventive therapy regimens 
may be the same whether the drug is administered daily or twice a week. 
Monitoring 
a) Adherence 
Patients on preventive therapy should be monitored during routine visits and by means of 
surprise checks for adherence to the preventive therapy. Pili counts, self-report and estimation 
of urinary acetyl INH may be useful in assessing adherence. Patients who interrupt therapy 
should be counseled about reasons for stopping treatment. Preventive therapy should only 
be restarted if the obstacles to adherence have been removed. The aim is to provide at least 
6 months of INH therapy during a 1-year period. 
b) Drug Toxicity 
Patients with symptoms suggestive of toxicity to medication should be evaluated immediately. 
Patients should be carefully educated about symptoms of hepatitis and instructed to attend 
the ciinic/OPD promptly should these occur, No toxicity from isoniazid was encountered in 
the Haitian study15. In the study from Spain32 9 of 86 (11 %) patients who started therapy had 
to discontinue it, in 6 cases because of hepatotoxicity. But in our experience at Tuberculosis 
Research Centre33preventive therapy with isoniazid can be safely employed in HIV infected 
patients, if baseline liver function tests are within normal limits. Another review article suggests 
an overall risk of death of 0.001% among subjects of all ages taking isoniazid for preventive 
therapy34. Data on rates of adverse effects in HIV infected individuals are not available: 
although experience suggests that toxicity from ATT drugs in advanced HIV disease is 
frequent35. In a community based programme in Florida36, of the 135 HIV infected patients 
who received RMP with PYZ for 2 months under DOT for latent TB infection, 5 patients had to 
discontinue treatment due to side effects and allergic skin reaction (n=4) and hepatitis (n=1). 
In the Ugandan HIV infected adults trial28, it was noted that side effects were higher in the 3 
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drugs group. In a recent meta analysis17 that compared INH monotherapy to short course 
multi drug regimen, it was noted that compared to INH monotherapy short course multi drug 
regimens were much more likely to require discontinuation of treatment due to adverse 
effects. 
c) Development of TB 
Preventive therapy should not be continued if the patient develops signs or symptoms of TB. 
The suspected cases must be properly evaluated for active TB and referred for treatment 
Drug Resistance 
Several studiescarried out in lndia show that primary drug resistance to isoniazid varies from 
6 to 13%37,38,39. Studies done at the Tuberculosis Research Centre40, Chennai from 1956 to 
1995 have shown that there is a gradual increase in the prevalence of primary drug resistance 
to INH from 3 to 13%. Hence, preventive therapy with INH alone may not be successful in 
such situations. Preventive treatment with INH (or other drugs) does not induce drug resistance 
if active tuberculosis is ruled out. In situations where there is a high default rate for anti-TB 
drugs, there is likely to be high default rate for the prophylaxis regimen as well. 
Contraindications to Preventive therapy 
Preventive therapy is contraindicated in patients with active tuberculosis and in patients with 
active (chronic or acute) hepatitis. Isoniazid should be given with caution to individuals who 
consume alcohol daily. Active tuberculosis must be excluded before beginning preventive 
therapy. 
Chemoprophylaxis in special situations 
Chemoprophylaxis in Pregnancy- Chemoprophylaxis for tuberculosis is recommended during 
pregnancy for HIV infected patients, who have a history of exposure to active tuberculosis, 
after active TB has been ruled out. In the absence of exposure to drug resistant TB. INH with 
pyridoxine (to reduce the risk of neurotoxcity) is the prophylactic agent of choice41. Some 
providers may choose to initiate prophylaxis after the first trimester to avoid teratogenicity. 
Chemoprophylaxis in children- Infants born to HIV infected mothers should have a Mantoux 
test (5-TU PPD or 1 -TU PPD RT23 with Tween 80) at or before age of 9-12 months and should 
be retested at least every 2-3 years41. Children exposed to persons who have active TB, 
should be administered preventive therapy after active TB has been ruled out. However, 
there have been no clinical trials of preventive therapy in HIV positive children 
Chemoprophylaxis in developing countries- In many of the developing countries, where there 
is a high prevalence of HIV and TB, many HIV infected individuals are likely to develop active 
TB. The first priority of National TB control Programme in such settings, is to treat all active 
cases of TB, render them non infectious and achieve a high cure rate. Although it could be 
accepted that preventive therapy should be offered to individuals who are diagnosed to be 
infected with both HIV and latent TB, such preventive therapy programme should not 
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compromise or undermine the priority of the TB control programme of diagnosing and 
curing patients with infectious tuberculosis. 
Secondary prophylaxis 
The rate of recurrent TB is higher in HIV-1 positive individuals than in HIV negative 
individuals with both re-activation and new infections contributing to recurrences42. A 
trial was conducted in Haiti43 to determine whether post treatment INH prophylaxls 
decreases the risk of recurrent TB. The rate of recurrent TB among patients who had 
completed a short course regimen was found to be 4.8 per 100 person years in HIV-1 
infected individuals and 0.4 per 100 person years in uninfected individuals (RR=10.7, 
95% CI 1.4-81.6). Among HIV-1 positive patients receiving INH for 6 months after TB 
treatment the TB recurrence rate was 1.4 per 100 person years and among HIV-1 
positive patients receiving placebo, it was 7.8 per 100 person years (0.18 (0.04-0.83). 
Another trial conducted in South Africa14 to determine the efficacy of secondary 
preventive therapy against TB among gold miners, concluded that the overall incidence 
of recurrent TB was reduced by 55% among men who received preventive therapy 
compared with those who did not (RR = 0.45,95% CI 0.26-0.78). It also showed that the 
impact of secondary preventive therapy to reduce TB recurrence was greatest among 
individuals with low CD4 cell counts. 
Cost Efficacy 
Studies are being conducted to consider not just the efficacy but the feasibility and cost 
efficacy of preventive therapy in HIV infected people in countries with a high prevalence of 
TB. The unit cost to prevent future TB disease should be evaluated against the cost of 
successful treatment of TB cases under programme conditions. The need for and provision 
of preventive therapy should therefore depend on the HIV situation and local resources. A 
model-based analysis to assess the impact of preventive therapy on the prevalence of 
tuberculosis in HIV infected persons in contemporary Sub-Saharan Africa was carried 
out45. The model implementation showed that giving preventive therapy to 25% of HIV 
positive individuals with latent tuberculosis infection leads to a 3.9% reduction in the prevalence 
of tuberculosis in 10 years and a 5.1% reduction in 20 years. Doubling the preventive 
therapy coverage to 50% approximately doubles the effect size, suggesting a linear 
relationship within the 20-year period. This model-based analysis suggests that the impact 
of preventive therapy on tuberculosis in the population is likely to be small contrary to 
general belief. 
Effect of Preventive therapy on Mortality 
The combined estimate provided by the largest meta analysis23 shows a modest reduction 
in death rates in those subjects with a positive tuberculin skin test who took INH rather than 
placebo (RR=0.73 95% CI 0.57-0.95). In those with a negative tuberculin test the pooled 
relative risk for mortality was 1.02 (0.89 to 1.17). The overall estimate for all subjects in the trial 
did not differ significantly from unity, confirming that no substantial protection was conferred 
by interventions. 
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The Uganda efficacy study28 showed that survival did not differ among the different groups 
but subjects with anergy had a higher mortality rate than the PPD positive subjects. Although 
the individual benefits may be rather small, widespread implementation of preventive therapy 
would have some impact on mortality. 
Evaluation of Outcome of Preventive therapy 
Programmes or centers that offer PT should assess the effectiveness of PT regularly. This 
assessment should include attendance at scheduled appointments, adherence (number of 
persons started on preventive therapy and number completed), toxicity and withdrawals 
from therapy due to toxicity, number of suspected TB cases found by screening, and 
monitoring of therapy. Individual records should be maintained to document use of PT 
Individual information will be aggregated tor regular reports, which may be used by the TB 
programme to estimate future drug requirements. 
Current Recommendations for preventive therapy 
1) WHO recommendation of preventive therapy against TB for PLWHA- Isoniazid is the 
recommended drug (5mg/kg - maximum 300mg) as daily, self-administered therapy for 6 
months. Individuals should be seen monthly and given only one month's supply of medication 
at each visit. 
2) CDC recommendation of preventive therapy against JB - Isoniazid is chosen for prevention 
of tuberculosis in persons with HIV infection, 9 months is recommended rather than 6 months46. 
Rifampicin and Pyrazinamide may be offered daily for 2 months to contacts of patients with 
H resistant, Rifampicin susceptible TB. 
3) American Thoracic Society- Isoniazid is recommended for 12 months in persons infected 
with HIV infection. 
Implementation of preventive therapy in India 
In order to make an impact on the incidence of tuberculosis, preventive therapy has to be 
administered to a large number of people. The number of sites where a sufficient number of 
people know their HIV status, or where there is sufficient demand for and capacity of VCT 
services will limit delivery of preventive therapy. Preventive therapy should therefore be 
promoted as an intervention for those living with HIV, rather than as a primary strategy to 
control the public health burden of tuberculosis. 
Before a developing country can implement a preventive therapy programme it should be 
able to readily identify HIV infected persons through counseling services and there should be 
good collaboration between the TB and AIDS programmes. 
Most importantly, preventive therapy should be organized and integrated into health services 
and the cost of prevention must be affordable or fully supported by state/district health 
service. 
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Preventive therapy should not distract from the top priority goal for health services of 
preventing HIV infection and successfully treating infectious TB cases using the DOT 
strategy. Mass or indiscriminate use of chemoprophylaxis against TB in developing 
countries not only entails an enormous cost for drugs for millions of people but could 
also increase the chance of developing drug resistance among unscreened TB cases. 
Therefore assessing the cost effectiveness and feasibility of such a programme is the 
first requisite to instituting preventive therapy services in developing countries like 
India. 
Research Issues 
Trials evaluating the long-term effects of anti-tuberculosis chemoprophylaxis 
Influence of level of immunocompromise on effectiveness 
Operational research to identify ideal setting, method of delivery, monitoring for exclusion 
of active TB and adherence. 
Summary 
Treatment of latent tuberculosis infection reduces the risk of active TB in HIV positive 
individuals with a positive tuberculin skin test. The choice of regimen will depend on 
factors such as cost, adverse effects, adherence and drug resistance. Decisions about 
preventive therapy require a balance between the needs of the individual and those of 
TB control at a public health level. The challenge in resource limited countries will be to 
provide voluntary HIV testing and counseling, tuberculin skin testing and preventive 
therapy in a supervised fashion to benefit as many people as possible without 
endangering public health through undisciplined use of antituberculosis drugs. 
Preventive therapy is not an alternative to the DOT strategy for controlling TB, even in 
areas with a high prevalence of HIV. Preventive therapy should be part of the package 
of care available to persons living with HIV/AIDS. The next step should be to develop 
systems that greatly increase the accessibility of preventive therapy to people living 
with HIV in settings of high TB prevalence, while ensuring that the efficiency of TB 
control programmes are not compromised. This will require greater collaboration 
between those fighting TB and those fighting HIV/AIDS. 
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